TC BioPharm Board Changes Announced
Ticker: TCBWF · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1872812
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: TCBP
TL;DR
TC Biopharm shakes up its board and exec pay structure.
AI Summary
TC BioPharm (Holdings) plc announced on June 26, 2024, a change in its board of directors. Specifically, the company reported the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its officers. The filing details these changes in corporate governance and executive compensation.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, operational focus, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts or challenges within the company.
Key Players & Entities
- TC BioPharm (Holdings) plc (company) — Registrant
- June 26, 2024 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departure of officers?
The filing indicates the departure of certain officers but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing states the election of directors but does not list their names in this summary.
What are the key changes in compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers but does not detail the specifics of these changes.
What is the significance of the date June 26, 2024, for this filing?
June 26, 2024, is the date of the earliest event reported in this Form 8-K filing.
What is the company's primary business sector?
TC BioPharm (Holdings) plc is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 14.4 · Accepted 2024-06-28 16:30:35
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-24-025622.txt ( ) — 258KB
- tcbp-20240626.xsd (EX-101.SCH) — 4KB
- tcbp-20240626_def.xml (EX-101.DEF) — 26KB
- tcbp-20240626_lab.xml (EX-101.LAB) — 36KB
- tcbp-20240626_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 7KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) Maxim 1 , 2 Parklands Way , Holytown , Motherwell , Scotland , United Kingdom ML1 4WR (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: +44 (0) 141 433 7557 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing twenty Ordinary Shares, nominal value 0.0001 per share TCBP The Nasdaq Stock Market LLC Ordinary Shares, nominal value 0.0001 per share* N/A The Nasdaq Stock Market LLC Warrants TCBPW The Nasdaq Stock Market LLC * Not for trading, but only in connection with the listing of the American Depositary Shares on The NASDAQ Stock Market LLC. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 26, 2024, each of Mark Bonyhadi and Edward Niemzyck submitted his respective resignation to the board of directors of TC Biopharm (Holdings) PLC (the "Company"), effective immediately. The decision of each of Mark Bonyhadi and Edward Niemzyck to resign was not the result of any disagreement on any matter relating to the operations, policies or practices of the Company. - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 28, 2024 TC BIOPHARM (HOLDINGS) PLC By: /s/ Martin Thorp Martin Thorp Chief Financial Officer - 3 -